Marker Therapeutics is trading 10.6% down today at $1.10 despite no new company-specific headlines or fundamental updates.
- The move appears to be idiosyncratic weakness in a thinly traded micro-cap stock.
- The company is underperforming a generally positive biotech sector and a mixed broader U.S. market.
- The decline suggests traders may be taking profits or reducing risk in the absence of a clear news catalyst.